ArticleInfectious diseases and therapy2026
Impact of Nirsevimab on Pediatric RSV-Related Lower Respiratory Tract Infections: A Retrospective Pre-Post Observational Study in Tuscany, Italy.
Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
introductionRespiratory syncytial virus (RSV) is the leading cause of respiratory infections and hospitalization among infants and a major burden on pediatric emergency department (EDs). Nirsevimab has recently been introduced for universal use in all infants entering their first RSV season. However, real-world data on its public health impact are still limited, particularly regarding attendances at pediatric ED.
methodsWe conducted a retrospective, observational, pre-post intervention study at the Meyer Children's Hospital (Tuscany, Italy). The 2024-25 RSV season, when nirsevimab was firstly implemented, was compared with the three preceding seasons. ED attendances, hospitalization, and pediatric intensive care unit (PICU) admissions for lower respiratory tract infections (LRTIs) of any etiology were analyzed.
resultsDuring the 2024-25 season, overall ED attendances for LRTIs, regardless of etiology, decreased by 67.3%. Hospital admissions for LRTIs dropped by 64.7%, and PICU admissions by 86.2%. RSV-confirmed LRTIs declined by 96.5%.
conclusionsUniversal nirsevimab prophylaxis markedly reduced the burden of respiratory infections in eligible infants, leading to a significant reduction in the use of healthcare resources, including ED visits, hospitalization, and PICU admissions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.